Cargando…
Distinct effect of body mass index by sex as a prognostic factor in localized renal cell carcinoma treated with nephrectomy ~ data from a multi-institutional study in Japan ~
BACKGROUND: We assessed the prognostic value of body mass index (BMI) in Asian patients with localized RCC who underwent nephrectomy. METHODS: A total of 665 patients who underwent nephrectomy for localized RCC were enrolled in the present study and divided into the two BMI groups: i.e., BMI < 25...
Autores principales: | Tsutsumi, Takeshi, Komura, Kazumasa, Hashimoto, Takeshi, Muraoka, Ryu, Satake, Naoya, Matsunaga, Tomohisa, Tsujino, Takuya, Yoshikawa, Yuki, Takai, Tomoaki, Minami, Koichiro, Taniguchi, Kohei, Tanaka, Tomohito, Uehara, Hirofumi, Hirano, Hajime, Nomi, Hayahito, Ibuki, Naokazu, Takahara, Kiyoshi, Inamoto, Teruo, Ohno, Yoshio, Azuma, Haruhito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913463/ https://www.ncbi.nlm.nih.gov/pubmed/33639880 http://dx.doi.org/10.1186/s12885-021-07883-9 |
Ejemplares similares
-
The combination of preoperative platelet count and neutrophil lymphocyte ratio as a prognostic indicator in localized renal cell carcinoma
por: Tsujino, Takuya, et al.
Publicado: (2017) -
E74-like factor inhibition induces reacquisition of hormone sensitiveness decreasing period circadian protein homolog 1 expression in prostate cancer cells()
por: Koyama, Kohei, et al.
Publicado: (2015) -
Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort
por: Komura, Kazumasa, et al.
Publicado: (2019) -
Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report
por: Tsujino, Takuya, et al.
Publicado: (2017) -
Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Uchimoto, Taizo, et al.
Publicado: (2021)